CoChat

Metabolic network as a progression biomarker of premanifest Huntington’s disease

Open access
Tang, Chris C., Feigin, Andrew, Ma, Yilong, Habeck, Christian, Paulsen, Jane S., Leenders, Klaus L., Teune, Laura K., van Oostrom, Joost C.H., Guttman, Mark, Dhawan, Vijay, Eidelberg, David · 2013 · Journal of Clinical Investigation
Cited by 120

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

BACKGROUND: The evaluation of effective disease-modifying therapies for neurodegenerative disorders relies on objective and accurate measures of progression in at-risk individuals. Here we used a computational approach to identify a functional brain network associated with the progression of preclinical Huntington's disease (HD). METHODS: Twelve premanifest HD mutation carriers were scanned with [18F]-fluorodeoxyglucose PET to measure cerebral metabolic activity at baseline and again at 1.5, 4, and 7 years. At each time point, the subjects were also scanned with [11C]-raclopride PET and structural MRI to measure concurrent declines in caudate/putamen D2 neuroreceptor binding and tissue volume. The rate of metabolic network progression in this cohort was compared with the corresponding estimate obtained in a separate group of 21 premanifest HD carriers who were scanned twice over a 2-year period. RESULTS: In the original premanifest cohort, network analysis disclosed a significant spatial covariance pattern characterized by progressive changes in striato-thalamic and cortical metabolic activity. In these subjects, network activity increased linearly over 7 years and was not influenced by intercurrent phenoconversion. The rate of network progression was nearly identical when measured in the validation sample. Network activity progressed at approximately twice the rate of single region measurements from the same subjects. CONCLUSION: Metabolic network measurements provide a sensitive means of quantitatively evaluating disease progression in premanifest individuals. This approach may be incorporated into clinical trials to assess disease-modifying agents. TRIAL REGISTRATION: Registration is not required for observational studies. FUNDING: NIH (National Institute of Neurological Disorders and Stroke, National Institute of Biomedical Imaging and Bioengineering) and CHDI Foundation Inc.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci69411

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 120

Metadata

Authors
Tang, C. C., Feigin, A., Ma, Y., Habeck, C., Paulsen, J. S., Leenders, K. L., Teune, L. K., van Oostrom, J. C. H., Guttman, M., Dhawan, V., & Eidelberg, D.
Venue
Journal of Clinical Investigation
Published
2013-08-29
Volume
123
Issue
9
Pages
4076-4088
ISSN
0021-9738 (ISSN-L)
OpenAlex
W2081840097
Cited by
120
References
5
FWCI
4.51
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Metabolic network as a progression biomarker of premanifest Huntington’s disease. https://app.cochat.ai/papers/10.1172/jci69411
The paper
Tang, C. C., Feigin, A., Ma, Y., Habeck, C., Paulsen, J. S., Leenders, K. L., Teune, L. K., van Oostrom, J. C. H., Guttman, M., Dhawan, V., & Eidelberg, D. (2013). Metabolic network as a progression biomarker of premanifest Huntington’s disease. Journal of Clinical Investigation. https://doi.org/10.1172/jci69411

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.